Levilimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An immunoglobulin G1 (IgG1) monoclonal antibody directed against the human interleukin-6 receptor (IL-6R; IL6R; CD126), with potential immunomodulating activity. Upon administration, levilimab targets and binds to the soluble form of IL-6R (sIL-6R; IL-6sR), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.

**Synonyms:** - BCD 089 - BCD-089 - BCD089 - LEVILIMAB